Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere
Hypertrophic cardiomyopathy is the second most common cause of cardiomyopathy presenting during childhood and whilst its underlying aetiology is variable, the majority of disease is caused by sarcomeric protein gene variants. Sarcomeric disease can present at any age with highly variable disease phe...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2021.708679/full |
id |
doaj-d011ab1f07044d7baa2a907ff9acaa73 |
---|---|
record_format |
Article |
spelling |
doaj-d011ab1f07044d7baa2a907ff9acaa732021-07-02T06:56:18ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602021-07-01910.3389/fped.2021.708679708679Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac SarcomereGabrielle Norrish0Gabrielle Norrish1Ella Field2Ella Field3Juan P. Kaski4Juan P. Kaski5Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, United KingdomInstitute of Cardiovascular Sciences University College London, London, United KingdomCentre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, United KingdomInstitute of Cardiovascular Sciences University College London, London, United KingdomCentre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, United KingdomInstitute of Cardiovascular Sciences University College London, London, United KingdomHypertrophic cardiomyopathy is the second most common cause of cardiomyopathy presenting during childhood and whilst its underlying aetiology is variable, the majority of disease is caused by sarcomeric protein gene variants. Sarcomeric disease can present at any age with highly variable disease phenotype, progression and outcomes. The majority have good childhood-outcomes with reported 5-year survival rates above 80%. However, childhood onset disease is associated with considerable life-long morbidity and mortality, including a higher SCD rate during childhood than seen in adults. Management is currently focused on relieving symptoms and preventing disease-related complications, but the possibility of future disease-modifying therapies offers an exciting opportunity to modulate disease expression and outcomes in these young patients.https://www.frontiersin.org/articles/10.3389/fped.2021.708679/fullpaediatrichypertrophic cardiomyopathysarcomeresudden deathprogression |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gabrielle Norrish Gabrielle Norrish Ella Field Ella Field Juan P. Kaski Juan P. Kaski |
spellingShingle |
Gabrielle Norrish Gabrielle Norrish Ella Field Ella Field Juan P. Kaski Juan P. Kaski Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere Frontiers in Pediatrics paediatric hypertrophic cardiomyopathy sarcomere sudden death progression |
author_facet |
Gabrielle Norrish Gabrielle Norrish Ella Field Ella Field Juan P. Kaski Juan P. Kaski |
author_sort |
Gabrielle Norrish |
title |
Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere |
title_short |
Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere |
title_full |
Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere |
title_fullStr |
Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere |
title_full_unstemmed |
Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere |
title_sort |
childhood hypertrophic cardiomyopathy: a disease of the cardiac sarcomere |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pediatrics |
issn |
2296-2360 |
publishDate |
2021-07-01 |
description |
Hypertrophic cardiomyopathy is the second most common cause of cardiomyopathy presenting during childhood and whilst its underlying aetiology is variable, the majority of disease is caused by sarcomeric protein gene variants. Sarcomeric disease can present at any age with highly variable disease phenotype, progression and outcomes. The majority have good childhood-outcomes with reported 5-year survival rates above 80%. However, childhood onset disease is associated with considerable life-long morbidity and mortality, including a higher SCD rate during childhood than seen in adults. Management is currently focused on relieving symptoms and preventing disease-related complications, but the possibility of future disease-modifying therapies offers an exciting opportunity to modulate disease expression and outcomes in these young patients. |
topic |
paediatric hypertrophic cardiomyopathy sarcomere sudden death progression |
url |
https://www.frontiersin.org/articles/10.3389/fped.2021.708679/full |
work_keys_str_mv |
AT gabriellenorrish childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere AT gabriellenorrish childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere AT ellafield childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere AT ellafield childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere AT juanpkaski childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere AT juanpkaski childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere |
_version_ |
1721336742102958080 |